Intermittent hypoxia changes HIF-1α phosphorylation pattern in endothelial cells: Unravelling of a new PKA-dependent regulation of HIF-1α

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1773, Issue 10, 2007, Pages 1558-1571

  Toffoli, Sébastien ^a   Feron, Olivier ^b   Raes, Martine ^a   Michiels, Carine ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

HIF 1 ; Intermittent hypoxia; Neo angiogenesis; PKA; Tumor

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44;

ANGIOGENESIS; ARTICLE; CELL FUNCTION; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REOXYGENATION;

CELL HYPOXIA; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOQUINOLINES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXYGEN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES;

EID: 34848884803     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.06.002     Document Type: Article

References (70)

1. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
2. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat. Rev., Cancer 5 (2005) 423-435
3. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
4. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003) 677-684
5. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., and Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
6. Dor Y., Porat R., and Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol., Cell Physiol. 280 (2001) C1367-C1374
7. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev., Cancer 2 (2002) 727-739
8. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev., Cancer 3 (2003) 401-410
9. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., and Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60 (2000) 1388-1393
10. Benjamin L.E., Golijanin D., Itin A., Pode D., and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103 (1999) 159-165
11. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., and McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160 (2002) 985-1000
12. Dur R.E., and Aquino-Parsons C. Clinical relevance of intermittent tumour blood flow. Acta Oncol. 40 (2001) 929-936
13. Dur R.E., and Aquino-Parsons C. Non-constant tumour blood flow-implications for therapy. Acta Oncol. 40 (2001) 862-869
14. Bennewith K.L., and Durand R.E. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res. 64 (2004) 6183-6189
15. Baish J.W., and Jain R.K. Fractals and cancer. Cancer Res. 60 (2000) 3683-3688
16. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., and Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 427 (2004) 695
17. Wenger R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 16 (2002) 1151-1162
18. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5510-5514
19. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270 (1995) 1230-1237
20. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272 (1997) 22642-22647
21. Semenza G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107 (2001) 1-3
22. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., and Kaelin Jr. W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292 (2001) 464-468
23. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., and Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275 (2000) 25733-25741
24. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
25. Jewell U.R., Kvietikova I., Scheid A., Bauer C., Wenger R.H., and Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15 (2001) 1312-1314
26. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271 (1996) 17771-17778
27. Wenger R.H. Mammalian oxygen sensing, signalling and gene regulation. J. Exp. Biol. 203 (2000) 1253-1263
28. Durand R.E. Intermittent blood flow in solid tumours-An under-appreciated source of 'drug resistance'. Cancer Metastasis Rev. 20 (2001) 57-61
29. Denekamp J., and Dasu A. Inducible repair and the two forms of tumour hypoxia-time for a paradigm shift. Acta Oncol. 38 (1999) 903-918
30. Chaplin D.J., and Hill S.A. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br. J. Cancer 71 (1995) 1210-1213
31. Dewhirst M.W., Braun R.D., and Lanzen J.L. Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 723-726
32. Hill S.A., Pigott K.H., Saunders M.I., Powell M.E., Arnold S., Obeid A., Ward G., Leahy M., Hoskin P.J., and Chaplin D.J. Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br. J. Cancer., Suppl. 27 (1996) S260-S263
33. Pigott K.H., Hill S.A., Chaplin D.J., and Saunders M.I. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother. Oncol. 40 (1996) 45-50
34. Martinive P., Defresne F., Bouzin C., Saliez J., Lair F., Gregoire V., Michiels C., Dessy C., and Feron O. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 66 (2006) 11736-11744
35. Edgell C.J., McDonald C.C., and Graham J.B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 3734-3737
36. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
37. Minet E., Arnould T., Michel G., Roland I., Mottet D., Raes M., Remacle J., and Michiels C. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 468 (2000) 53-58
38. Mottet D., Dumont V., Deccache Y., Demazy C., Ninane N., Raes M., and Michiels C. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J. Biol. Chem. 278 (2003) 31277-31285
39. Treins C., Giorgetti-Peraldi S., Murdaca J., Monthouel-Kartmann M.N., and Van Obberghen E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. Mol. Endocrinol. 19 (2005) 1304-1317
40. Richard D.E., Berra E., Gothie E., Roux D., and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274 (1999) 32631-32637
41. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., Georgatsou E., Bonanou S., and Simos G. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J. Biol. Chem. 281 (2006) 33095-33106
42. Zhou J., Schmid T., Frank R., and Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J. Biol. Chem. 279 (2004) 13506-13513
43. Arsham A.M., Plas D.R., Thompson C.B., and Simon M.C. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem. 277 (2002) 15162-15170
44. Batmunkh C., Krajewski J., Jelkmann W., and Hellwig-Burgel T. Erythropoietin production: Molecular mechanisms of the antagonistic actions of cyclic adenosine monophosphate and interleukin-1. FEBS Lett. 580 (2006) 3153-3160
45. Kvietikova I., Wenger R.H., Marti H.H., and Gassmann M. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res. 23 (1995) 4542-4550
46. Marti H.H., Jung H.H., Pfeilschifter J., and Bauer C. Hypoxia and cobalt stimulate lactate dehydrogenase (LDH) activity in vascular smooth muscle cells. Pflugers Arch. 429 (1994) 216-222
47. Prabu S.K., Anandatheerthavarada H.K., Raza H., Srinivasan S., Spear J.F., and Avadhani N.G. Protein kinase A-mediated phosphorylation modulates cytochrome C oxidase function and augments hypoxia and myocardial ischemia related injury. J. Biol. Chem. 281 (2005) 2061-2070
48. Gao Y., Gao G., Long C., Han S., Zu P., Fang L., and Li J. Enhanced phosphorylation of cyclic AMP response element binding protein in the brain of mice following repetitive hypoxic exposure. Biochem. Biophys. Res. Commun. 340 (2006) 661-667
49. Takagi H., King G.L., Ferrara N., and Aiello L.P. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Investig. Ophthalmol. Vis. Sci. 37 (1996) 1311-1321
50. Takagi H., King G.L., Robinson G.S., Ferrara N., and Aiello L.P. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Investig. Ophthalmol. Vis. Sci. 37 (1996) 2165-2176
51. Marshall J.M. Adenosine and muscle vasodilatation in acute systemic hypoxia. Acta Physiol. Scand. 168 (2000) 561-573
52. Casanello P., Torres A., Sanhueza F., Gonzalez M., Farias M., Gallardo V., Pastor-Anglada M., San Martin R., and Sobrevia L. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circ. Res. 97 (2005) 16-24
53. Adair T.H. Growth regulation of the vascular system: an emerging role for adenosine. Am. J. Physiol., Regul. Integr. Comp. Physiol. 289 (2005) R283-R296
54. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., and Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46 (1994) 143-156
55. Daval J.L., Nicolas F., and Doriat J.F. Adenosine physiology and pharmacology: how about A2 receptors?. Pharmacol. Ther. 71 (1996) 325-335
56. Michiels C., Arnould T., Knott I., Dieu M., and Remacle J. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am. J. Physiol. 264 (1993) C866-C874
57. Michiels C., Renard P., Bouaziz N., Heck N., Eliaers F., Ninane N., Quarck R., Holvoet P., and Raes M. Identification of the phospholipase A(2) isoforms that contribute to arachidonic acid release in hypoxic endothelial cells: limits of phospholipase A(2) inhibitors. Biochem. Pharmacol. 63 (2002) 321-332
58. Tsuboi K., Sugimoto Y., and Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 68-69 (2002) 535-556
59. Ray C.J., Abbas M.R., Coney A.M., and Marshall J.M. Interactions of adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: in vivo and in vitro studies. J. Physiol. 544 (2002) 195-209
60. Ray C.J., and Marshall J.M. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J. Physiol. 570 (2006) 85-96
61. Yuan G., Adhikary G., McCormick A.A., Holcroft J.J., Kumar G.K., and Prabhakar N.R. Role of oxidative stress in intermittent hypoxia-induced immediate early gene activation in rat PC12 cells. J. Physiol. 557 (2004) 773-783
62. Ryan S., McNicholas W.T., and Taylor C.T. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem. Biophys. Res. Commun. 355 (2007) 728-733
63. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60 (2000) 1541-1545
64. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
65. Li F., Sonveaux P., Rabbani Z.N., Liu S., Yan B., Huang Q., Vujaskovic Z., Dewhirst M.W., and Li C.Y. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell 26 (2007) 63-74
66. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16 (2002) 1466-1471
67. Yasinska I.M., and Sumbayev V.V. S-nitrosation of Cys-800 of HIF-1alpha protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 549 (2003) 105-109
68. Suzuki H., Tomida A., and Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20 (2001) 5779-5788
69. Vexler A.M., and Litinskaya L.L. Changes in intracellular pH induced by hyperthermia and hypoxia. Int. J. Hypertherm. 2 (1986) 75-81
70. Nakamura T., Ozawa S., Kitagawa Y., Ueda M., Kubota T., and Kitajima M. Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. Oncol. Rep. 15 (2006) 79-83